Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
J.-Y. Douillard(European Society for Medical Oncology), R. Sidhu(Amgen (United States)), Maria Błasińska-Morawiec(Copernicus Memorial Hospital), Josep Tabernero(Deaconess Hospital), Paul Ruff, Salvatore Siena(University of Milan), G. Bodoky(Unified Szent István and Szent László Hospital), Ilona Kocáková(Masaryk University), Kelly S. Oliner(Amgen (United States)), Mario Barugel, M. Rother(Credit Valley Hospital), J Cassidy(Cancer Research UK), Fernando Rivera(Marqués de Valdecilla University Hospital), Ronald L. Burkes(Mount Sinai Hospital), Martin Šmakal(Nemocnice Na Pleši), Ying Tian(NARI Group (China)), Feng Xu(North Sichuan Medical University), J.-L. Canon(Grand Charleroi Hospital), Yves Humblet(Deventer Ziekenhuis), David Cunningham(Royal Marsden NHS Foundation Trust), Jacek Jassem(Gdańsk Medical University)
Cited by 603
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Genomic analysis identifies association of <i>Fusobacterium</i> with colorectal carcinoma
|Genome Research|2011|2k